

## References

### I-214

1. Reblozyl® (luspatercept-aamt) injection, for subcutaneous use [package insert]. Celgene Corporation. Summit, NJ. Revised 08/2023.
2. Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with  $\beta$ -thalassemia. *Blood*. 2019;133(12):1279-1289.
3. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Luspatercept.
4. Micromedex DrugDex Compendium®. 2023. Luspatercept.
5. Fenaux P, Platzbecker GJ, Mufti G, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. 2020;382:140-51.
6. Cappellini MD, Viprakasit V, Taher AT, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent  $\beta$ -thalassemia. 2020;382:1219-31.
7. Luspatercept-aamt In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated December 9, 2019.
8. National Comprehensive Cancer Network (NCCN). Drugs and Biologics Compendium®. 2023. Luspatercept-aamt.
9. Platzbecker U, Della Porta MG, Zeidan AM, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. *Lancet*. 2023;402(10399):p373-385.